Psychogenic Acute Myositis.

Speciality: Pediatrics


Speaker:

Dr. Rajesh Gadia | DNB (Med)

Description:

A warm welcome to all the medical professionals in this interesting session on Psychogenic Acute Myositis.

Clinical Presentation:
Psychogenic acute myositis is a rare condition characterized by sudden onset of muscle inflammation and pain, often triggered or exacerbated by psychological factors rather than physical causes. Patients typically present with muscle tenderness, weakness, and swelling, primarily affecting the major muscle groups. Unlike other forms of myositis, psychogenic myositis does not have an identifiable organic cause, and the symptoms may fluctuate with the patient's emotional state.
Pathophysiology:
The exact mechanism underlying psychogenic acute myositis remains unclear. It is believed that psychological stress can lead to muscle tension and altered pain perception, potentially resulting in muscle inflammation and pain. This condition may be associated with somatoform disorders, where psychological distress manifests as physical symptoms. The interplay between the nervous system and muscle tissue is complex, involving neuroendocrine responses to stress.
Diagnostic Approach:
Diagnosing psychogenic acute myositis involves a thorough clinical evaluation to rule out other potential causes of muscle inflammation, such as infections, autoimmune diseases, or metabolic disorders. Laboratory tests, including muscle enzymes (e.g., creatine kinase), inflammatory markers, and electromyography (EMG), are typically normal or only mildly elevated. Psychological assessme

See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

'Chemo brain' cognitive issues linked to poor lymphatic-system drainage

2.

AI System Beats Radiologists in Detecting Clinically Significant Prostate Cancer

3.

A consensus statement from researchers on the proper use of Lu-177 PSMA-617 radionuclide therapy and patient selection is published.

4.

According to JAMA, 5 alpha-reductase inhibitors are not significantly linked to prostate cancer mortality.

5.

Researchers can now forecast how prostate cancer bone metastases will react to radium-223 treatment.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot